Updates on The NGAL Test clinical trials for the US FDA De Novo application

Plus rights issue initiated with pre-emptive subscription rights for existing shareholders; updates on the 2021 financial estimate and guidance for 2022

March 7, 2022

New Composition of the Management Board of BioPorto A/S

New CEO Anthony Pare and CFO Neil A. Goldman appointed; Peter Mørch Eriksen to join as a member of the Board of Directors

November 19, 2021

BioPorto Successfully Completes Interim Analysis of Data from Pivotal Study of NGAL in Pediatrics with Encouraging Results

Includes data collected from six different leading US children’s hospitals over a twelve-month period.

August 31, 2021

BioPorto Initiates Patient Enrollment for US Pediatric Study of The NGAL Test™

First patients enrolled at Cincinnati Children’s Hospital, a leading US center for critical care nephrology

June 23, 2020

BioPorto Submits Pediatric Application to FDA for The NGAL Test™ Under Breakthrough Designation

First test focused on risk assessment of Acute Kidney Injury in pediatric patients

May 15, 2019